Physician profile
Ginger Brounce
NPI 1013012665
$2,000.16
in general payments reported to CMS, 2019-2025
17 companies · $458 in 2025
The $458 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $506 · 2022: $293 · 2023: $247 · 2024: $496 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,200.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $360.87 | 2021-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $298.28 | 2021-2025 | Zepbound, Mounjaro |
| Exact Sciences Corporation | $295.40 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $207.74 | 2021-2025 | Airsupra, Farxiga |
| Abbvie INC. | $199.85 | 2021-2024 | |
| Pfizer INC. | $191.86 | 2021-2025 | |
| Novo Nordisk INC | $143.23 | 2022-2024 | Wegovy |
| Abbott Laboratories | $86.79 | 2021-2022 | |
| Dexcom, INC. | $46.37 | 2024-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $43.93 | 2023 | Veozah |
| Glaxosmithkline, LLC. | $39.71 | 2022-2023 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.71 | 2021 | |
| Bausch Health US, LLC | $17.67 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.71 | 2024 | Nuedexta |
| Avanir Pharmaceuticals, INC. | $14.19 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $13.85 | 2023 | Aptima |
| Genentech USA, INC. | $3.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ginger Brounce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.